Abstract
Purpose The prevalence of myopia varies significantly across the globe. This may be a consequence of differences in exposure to lifestyle risk factors or differences in genetic susceptibility across ancestry groups. “Trans-ancestry genetic correlation” quantifies the similarity in genetic predisposition to a trait or disease between different populations. We aimed to calculate the trans-ancestry genetic correlation of refractive error across a diverse range of ancestry groups (European, South Asian, East Asian and African) using recently developed approaches.
Methods Two methods were applied: (1) trans-ancestry genetic correlation with unbalanced data resources (TAGC-UDR) and (2) trans-ancestry bivariate genomic-relatedness-based restricted maximum-likelihood (TAB-GREML). TAGC-UDR analyses were carried out for UK Biobank participants of European (n=107,668; n=3,500), East Asian (n=972), South Asian (n=4,303) and African (n=3,877) ancestry. TAB-GREML analyses were carried out for participants of European (n=10,000), South Asian (n=4,303) and African (n=3,877) ancestry.
Results TAGC-UDR analyses suggested the trans-ancestry genetic correlation of refractive error was in the range 0.7–1.0 for the European vs. African, European vs. East Asian and European vs. South Asian ancestry pairs. The TAB-GREML estimates were consistent with the TAGC-UDR findings. Precision of the estimates was limited, reflecting the modest sample sizes of the non-European samples.
Conclusion The findings support existing evidence that genetic susceptibility to refractive error is largely shared between Europeans and East Asians, and further suggest that genetic susceptibility to refractive error is largely shared across Europeans, Africans and South Asians. The results imply that differences in geographical variation in myopia prevalence are mostly driven by lifestyle factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Supported by Project Grant (24WG201) from the Welsh Government and Fight for Sight; UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee [grant number EP/Y032292/1]. Funded by the European Union (Project 101119501 - MyoTreat - HORIZON-MSCA-2022-DN-01). Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or UKRI. Neither the European Union nor the granting authority can be held responsible for them.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The United Kingdom NHS Research Ethics Committee gave ethical approval to UK Biobank for this work (Reference: 11/NW/0382).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial Support Supported by Project Grant (24WG201) from the Welsh Government and Fight for Sight; UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee [grant number EP/Y032292/1]. Funded by the European Union (Project 101119501 — MyoTreat — HORIZON-MSCA-2022-DN-01). Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or UKRI. Neither the European Union nor the granting authority can be held responsible for them.
Data Availability
UK Biobank data are available via application at https://www.ukbiobank.ac.uk.
